XML 112 R62.htm IDEA: XBRL DOCUMENT
v3.24.1

Genevant Agreement (Additional Information) (Details) - USD ($) $ in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2023 | Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |
Research and Development Expense, Total | $ 57,250 | $ 42,201
Reimbursements with in Research and Development Expense | 1,200 |
Genevant Agreement [Member] |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |
Research and Development Expense, Total | 2,500 |
Revenue recognized commercialization milestone payments to receive | 57,000 |
Genevant Agreement [Member] | Maximum [Member] | Phase 3 Clinical Trial |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |
Milestone payment | 13,500 |
Genevant Agreement [Member] | Maximum [Member] | Phase2b Clinical Trial |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |
Milestone payment | $ 27,000 |

X
- Definition Contract with customer liability revenue recognized from commercialization milestones. + References No definition available. + Details
Name: | krro_ContractWithCustomerLiabilityRevenueRecognizedFromCommercializationMilestones
Namespace Prefix: | krro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment + References No definition available. + Details
Name: | krro_MilestonePayment
Namespace Prefix: | krro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reimbursements with in Research and Development Expense + References No definition available. + Details
Name: | krro_ReimbursementsWithInResearchAndDevelopmentExpense
Namespace Prefix: | krro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=krro_GenevantAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=krro_Phase3ClinicalTrailMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=krro_Phase2BClinicalTrial1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |